🇺🇸 FDA
Pipeline program

low titer whole blood

STUDY20110430

Phase 3 mab completed

Quick answer

low titer whole blood for Hemorrhagic Shock is a Phase 3 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Hemorrhagic Shock
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials